WELCOME TO HYBRID 2024

Paris, 
8 & 9 February 2024

Welcome to HYBRIDAYS 2024, an international event that brings together the foremost Academic research teams, leading innovative French Start-ups, and Pharmaceutical powerhouses, all driven by their visionary pursuits of the Next Generations of Gene and Cell Therapies.
Yet, Hybrid is not just an event; it signifies an evolution.
It emerges from the convergence of two influential forces, one of which was the esteemed RIR.
Since 2009, the RIR (International R&D Meetings), orchestrated by ARIIS and AVIESAN, has been a nexus where pharmaceutical giants and cutting-edge academic research teams converge.
And as of 2021, the RIRs have fused their strengths with the dynamic RIBs (International Biotechnology Meetings) to birth HYBRID, a force that is poised to revolutionize the landscape of science and innovation.

NEXT GENERATIONS OF GENE AND CELL THERAPIES

HYBRID 2024

ARIIS - the health industry alliance for research and innovation, Bpifrance - the French Public Investment Bank, France Biotech - French trade association of biotechnology companies, INSERM - French National Institute of Health and Medical Research, and Leem - the French union of pharmaceutical industries have joined forces to organize HYBRID :

  • An international research and innovation meeting, bringing together academic researchers, start-ups and industry in Paris.

  • A unique opportunity to discover and meet the best of French research and innovation (research teams, start-ups) and international industrial teams.

  • A two-day event alternating keynotes, pitches and B to B meetings, paving the way for future collaborations and partnerships with the French innovation ecosystem.
Image

2024 Edition : NEXT GENERATION OF GENE AND CELL THERAPIES

  • Vector-derived gene therapy (viral and non viral)
  • Novel Genome editing approaches
  • Nucleic acid therapeutics
  • Cell therapies (universal cells, reprogrammed cells,…)
  • Next generation of CAR
  • Novel approaches such as Exosomes for delivery
  • Short-, medium- and long-term tolerance and toxicity

A COMPLETE ECOSYSTEM

HYBRID has been designed with the aim to go one step further compared to previous editions by:

  • Federating the French National Institute of Health and Medical Research INSERM together with the French industrial alliances (ARIIS), the French union of pharmaceutical companies (Leem), the French biotech alliance (France Biotech) and the French investment bank (Bpifrance)
  • Gathering top talented French scientists, promising French start-ups and international industry leaders during two days
  • Enhancing the entire French ecosystem and promoting public & private partnerships, a key generator for innovation
HYBRID_home_schema.jpg